Forum Alert: Pharmos Corporation will Present at the Informed Investors Biotechnology / Healthcare / Pharmaceutical Investor Forum at The Princeton Club of New York on Tuesday, June 15, 2005, 2:35 pm ET
Iselin NJ, June 6, 2005 – Iselin, NJ – June 6, 2005 /Business Wire/ — Pharmos Corporation (NasdaqSC: PARSD) will present at the following forum:
| What: | Informed Investors Biotechnology / Healthcare / Pharmaceutical Investor Forum |
| When: | June 15, 2005 @ 2:35 PM Eastern Time |
| Sponsors: | Barron’s, The Wall Street Journal, The American Stock Exchange and Business Wire |
| Keynote Presentations: | Lynn Sutherland, M.S., M.B.A. – President, Sutherland Consulting Dr. Navdeep Jaikaria, Senior Biotechnology Analyst, Rodman & Renshaw, LLC |
| Where: | The Princeton Club of New York, 15 West 43rd Street., New York City, NY 10036 |
| How to attend: | Pre-registration is necessary. To register, contact Cary Loeser, cloeser@wilink.com, or 804-327-3407. You may also call Customer Service at 888-301-6618, or register at the following link: http://www.informedinvestors.com/CustomEvent/89559/index.asp
If you are unable to attend the live event, the forum will be available via webcast at http://www.informedinvestors.com/CustomEvent/89559/index.asp |
| Contact: | Gale Smith, Gale.Smith@pharmos-us.com, 732-452-9556 X 204 |
Pharmos discovers and develops novel therapeutics to treat a range of indications, in particular neurological and inflammatory disorders. The Company’s core proprietary technology platform focuses on discovery and development of synthetic cannabinoid compounds. Cannabinor, the lead CB2-selective receptor agonist candidate, is scheduled to begin Phase I safety studies in the second half of 2005 and, if successful, enter Phase II testing in pain indications around yearend or early 2006. From the dextrocannabinoid family, the neuroprotective drug candidate dexanabinol recently completed a Phase IIa trial as a preventive agent against post-surgical cognitive impairment. Other compounds from Pharmos’ proprietary synthetic cannabinoid library are in pre-clinical studies targeting pain, multiple sclerosis, rheumatoid arthritis and other disorders.
FORUM CONTACT: Cary Loeser, Informed Investors, 804-327-3407, cloeser@wilink.com
Web site: http://www.informedinvestors.com
Contacts
Pharmos U.S.:
Gale Smith
(732) 452-9556
Pharmos Israel:
Irit Kopelov
011-972-8-940-9679
The Ruth Group, Inc.
John Quirk (investors)
(646) 536-7029
Janine McCargo (media)
(646) 536 7033